Kaetlyn T. Ryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kaetlyn T. Ryan has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Mostafa Zamanian
Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
13 shared publications - Nicholas J. Wheeler
Department of Biology, University of Wisconsin-Eau Claire, Eau Claire, WI
9 shared publications - Kendra J. Gallo
University of Wisconsin-Madison
7 shared publications - Clair R. Henthorn
Affiliation Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
3 shared publications - John D. Chan
Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
2 shared publications - Nathalie Dinguirard
Affiliation Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
2 shared publications
Latest Publications
- Open Access
High-throughput phenotypic profiling of insecticide responses in mosquito larvae
Extensive use of insecticides is increasing resistance risks that could severely reduce the control of mosquito vectors that transmit infectious agents of Neglected Tropical Diseases. Addressing resistance threats by discovering new insecticides can be challenging because of the limited throughput and translatability of existing in vitro screening pipelines. Acquiring multiple phenotypic endpoints of larvae could alleviate these restrictions by more thoroughly profiling drug effects on whole organisms, providing leads to compounds with novel mechanisms of action, and increasing screening throughput compared to adult-stage assays. Here, we establish a pair of assays for profiling motility and development traits in larval-stage mosquitoes at a higher scale than standard larvicidal screening techniques. We optimized assay parameters and developed novel image processing approaches that enable relatively high throughput screening of chemical compounds on single larvae within a screen with condition replicates. We tested the assay with an insect growth regulator (S-methoprene), a slow-acting pyrrole (chlorfenapyr), and two microbial larvicides (Spinosad and Lysinibacillus sphaericus ). These measurements aligned well with known insecticide mechanisms, and dose response curves established assay baselines for comparison in future screens. Finally, we present ways in which the assay design can be modified across different imaging technologies, showing the flexibility of the screening approach. Author Summary: Insecticides are often used to control the transmission of Neglected Tropical Disease agents that are spread by mosquitoes. Growing risks of resistance necessitates assessing the efficacy of current insecticides and efforts to discover novel drugs. Performing these types of research can be challenging because of the complexity of mosquito life cycles and the limited throughput of existing screening pipelines. To address these restrictions, we developed a pair of assays that profile the motility and development of mosquito larvae after drug exposure and involve relatively high-throughput imaging and data processing. We then optimized these protocols to work with three species of mosquitoes and validated the assay by profiling the effects of four frequently used insecticides. Measurements and observations with this screen could be partially explained by the known mechanisms of these treatments, and dose response curves provided potential comparison points for future screens. We also showed the flexibility of this screening method to different imaging approaches, adding potential for use across laboratories with different resources.
Open AccessHigh-throughput phenotypic profiling of insecticide responses in mosquito larvae
Extensive use of insecticides is increasing resistance risks that could severely reduce the control of mosquito vectors that transmit infectious agents of Neglected Tropical Diseases. Addressing resistance threats by discovering new insecticides can be challenging because of the limited throughput and translatability of existing in vitro screening pipelines. Acquiring multiple phenotypic endpoints of larvae could alleviate these restrictions by more thoroughly profiling drug effects on whole organisms, providing leads to compounds with novel mechanisms of action, and increasing screening throughput compared to adult-stage assays. Here, we establish a pair of assays for profiling motility and development traits in larval-stage mosquitoes at a higher scale than standard larvicidal screening techniques. We optimized assay parameters and developed novel image processing approaches that enable relatively high throughput screening of chemical compounds on single larvae within a screen with condition replicates. We tested the assay with an insect growth regulator (S-methoprene), a slow-acting pyrrole (chlorfenapyr), and two microbial larvicides (Spinosad and Lysinibacillus sphaericus ). These measurements aligned well with known insecticide mechanisms, and dose response curves established assay baselines for comparison in future screens. Finally, we present ways in which the assay design can be modified across different imaging technologies, showing the flexibility of the screening approach. Author Summary: Insecticides are often used to control the transmission of Neglected Tropical Disease agents that are spread by mosquitoes. Growing risks of resistance necessitates assessing the efficacy of current insecticides and efforts to discover novel drugs. Performing these types of research can be challenging because of the complexity of mosquito life cycles and the limited throughput of existing screening pipelines. To address these restrictions, we developed a pair of assays that profile the motility and development of mosquito larvae after drug exposure and involve relatively high-throughput imaging and data processing. We then optimized these protocols to work with three species of mosquitoes and validated the assay by profiling the effects of four frequently used insecticides. Measurements and observations with this screen could be partially explained by the known mechanisms of these treatments, and dose response curves provided potential comparison points for future screens. We also showed the flexibility of this screening method to different imaging approaches, adding potential for use across laboratories with different resources.
- Open Access
- 29 July 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (7) , e1014485
Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs
The anthelmintics ivermectin, albendazole, and diethylcarbamazine are the backbone of mass drug administration (MDA) campaigns targeting human filariasis, yet their direct effects on parasites are still not fully defined or understood. The clinical effects of these drugs are stage dependent, resulting in effective clearance of circulating microfilariae but only limited activity against adult worms, a pattern that complicates disease surveillance and elimination efforts. Although molecular targets have been identified or proposed for some antifilarial drugs, their precise modes of action remain opaque, and conventional in vitro assays of motility or viability have generally failed to reflect pharmacologically relevant effects. There is growing evidence that cryptic phenotypes involving altered host-parasite interactions, including changes in parasite secretions, may help reconcile these discrepancies. Focusing on the causative species of lymphatic filariasis, we used high content imaging and quantitative mass spectrometry to enable deeper phenotypic profiling of drug responses in microfilariae and adult worms exposed to antifilarial compounds. In microfilariae, altered environmental conditions (temperature and salinity) lead to modest ivermectin effects on motility at therapeutic concentrations. In adult parasites, we show that drug responses vary with worm age and that different anthelmintics induce distinct changes in the secretory proteome. This improved phenotypic resolution advances our understanding of drug action in intra-host stages and highlights how antifilarial drugs can alter secretory cargo relevant to the detection of adult parasites that persist after drug treatment.
- 29 July 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (7) , e1014485
Open AccessDeep phenotypic profiling uncovers cryptic effects of antifilarial drugs
The anthelmintics ivermectin, albendazole, and diethylcarbamazine are the backbone of mass drug administration (MDA) campaigns targeting human filariasis, yet their direct effects on parasites are still not fully defined or understood. The clinical effects of these drugs are stage dependent, resulting in effective clearance of circulating microfilariae but only limited activity against adult worms, a pattern that complicates disease surveillance and elimination efforts. Although molecular targets have been identified or proposed for some antifilarial drugs, their precise modes of action remain opaque, and conventional in vitro assays of motility or viability have generally failed to reflect pharmacologically relevant effects. There is growing evidence that cryptic phenotypes involving altered host-parasite interactions, including changes in parasite secretions, may help reconcile these discrepancies. Focusing on the causative species of lymphatic filariasis, we used high content imaging and quantitative mass spectrometry to enable deeper phenotypic profiling of drug responses in microfilariae and adult worms exposed to antifilarial compounds. In microfilariae, altered environmental conditions (temperature and salinity) lead to modest ivermectin effects on motility at therapeutic concentrations. In adult parasites, we show that drug responses vary with worm age and that different anthelmintics induce distinct changes in the secretory proteome. This improved phenotypic resolution advances our understanding of drug action in intra-host stages and highlights how antifilarial drugs can alter secretory cargo relevant to the detection of adult parasites that persist after drug treatment.
- Open Access
- 12 March 2026
- Published by Wiley in New Phytologist
- Vol. 250 (3) , 1863-1883
Equipped for success: genomes and metabolomes of the European Amanita muscaria are conserved in its novel South African range
Summary: Plants and soils have been moved around the world for centuries, but invasive mushrooms receive scant attention. The Amanita muscaria species complex was introduced to South Africa in the context of forestry, but its origins, ecology and recent evolution are unstudied. We sequenced the genomes of 24 Northern and Southern Hemisphere A. muscaria , built phylogenies and reconstructed its South African history. We identified the biosynthetic gene clusters (BGCs) encoding specialized metabolites (SMs). We subsequently extracted mushrooms' metabolites and used mass spectrometry data to group SMs into unique molecular families (MFs). We tested metabolites for bioactivity against diverse microbes and animals. We identify Europe as the origin of South African A. muscaria . A highly conserved group of BGCs is found in nearly all European and African genomes, and only 13 of 273 MFs are unique to South Africa. Metabolites extracted from all mushrooms kill nematodes, while microbes and flies appear unaffected. The nearly global distribution of the fly agaric results from multiple introductions of a single European clade to the Southern Hemisphere. Despite its long history in South Africa, the fungus has not lost any of its BGCs, suggesting a conservation of function(s) across multiple continents.
- 12 March 2026
- Published by Wiley in New Phytologist
- Vol. 250 (3) , 1863-1883
Open AccessEquipped for success: genomes and metabolomes of the European Amanita muscaria are conserved in its novel South African range
Summary: Plants and soils have been moved around the world for centuries, but invasive mushrooms receive scant attention. The Amanita muscaria species complex was introduced to South Africa in the context of forestry, but its origins, ecology and recent evolution are unstudied. We sequenced the genomes of 24 Northern and Southern Hemisphere A. muscaria , built phylogenies and reconstructed its South African history. We identified the biosynthetic gene clusters (BGCs) encoding specialized metabolites (SMs). We subsequently extracted mushrooms' metabolites and used mass spectrometry data to group SMs into unique molecular families (MFs). We tested metabolites for bioactivity against diverse microbes and animals. We identify Europe as the origin of South African A. muscaria . A highly conserved group of BGCs is found in nearly all European and African genomes, and only 13 of 273 MFs are unique to South Africa. Metabolites extracted from all mushrooms kill nematodes, while microbes and flies appear unaffected. The nearly global distribution of the fly agaric results from multiple introductions of a single European clade to the Southern Hemisphere. Despite its long history in South Africa, the fungus has not lost any of its BGCs, suggesting a conservation of function(s) across multiple continents.
- Open Access
Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs
The anthelmintics ivermectin, albendazole, and diethylcarbamazine are the backbone of mass drug administration (MDA) campaigns targeting human filariasis, yet their direct effects on parasites are still not fully defined or understood. The clinical effects of these drugs are stage dependent, resulting in effective clearance of circulating microfilariae but only limited activity against adult worms, a pattern that complicates disease surveillance and elimination efforts. Although molecular targets have been identified or proposed for some antifilarial drugs, their precise modes of action remain opaque, and conventional in vitro assays of motility or viability have generally failed to reflect pharmacologically relevant effects. There is growing evidence that cryptic phenotypes involving altered host-parasite interactions, including changes in parasite secretions, may help reconcile these discrepancies. Focusing on the causative species of lymphatic filariasis, we used high content imaging and quantitative mass spectrometry to enable deeper phenotypic profiling of drug responses in microfilariae and adult worms exposed to antifilarial compounds. In microfilariae, altered environmental conditions (temperature and salinity) lead to modest ivermectin effects on motility at therapeutic concentrations. In adult parasites, we show that drug responses vary with worm age and that different anthelmintics induce distinct changes in the secretory proteome. This improved phenotypic resolution advances our understanding of drug action in intra-host stages and highlights how antifilarial drugs can alter secretory cargo relevant to the detection of adult parasites that persist after drug treatment.
Open AccessDeep phenotypic profiling uncovers cryptic effects of antifilarial drugs
The anthelmintics ivermectin, albendazole, and diethylcarbamazine are the backbone of mass drug administration (MDA) campaigns targeting human filariasis, yet their direct effects on parasites are still not fully defined or understood. The clinical effects of these drugs are stage dependent, resulting in effective clearance of circulating microfilariae but only limited activity against adult worms, a pattern that complicates disease surveillance and elimination efforts. Although molecular targets have been identified or proposed for some antifilarial drugs, their precise modes of action remain opaque, and conventional in vitro assays of motility or viability have generally failed to reflect pharmacologically relevant effects. There is growing evidence that cryptic phenotypes involving altered host-parasite interactions, including changes in parasite secretions, may help reconcile these discrepancies. Focusing on the causative species of lymphatic filariasis, we used high content imaging and quantitative mass spectrometry to enable deeper phenotypic profiling of drug responses in microfilariae and adult worms exposed to antifilarial compounds. In microfilariae, altered environmental conditions (temperature and salinity) lead to modest ivermectin effects on motility at therapeutic concentrations. In adult parasites, we show that drug responses vary with worm age and that different anthelmintics induce distinct changes in the secretory proteome. This improved phenotypic resolution advances our understanding of drug action in intra-host stages and highlights how antifilarial drugs can alter secretory cargo relevant to the detection of adult parasites that persist after drug treatment.
- Open Access
Nematicidal indole oxazoles and chemoattractants from soil bacteria
Ecological interactions between bacteria and nematodes in many environments provide a basis for the prediction that diverse bacteria produce anti-nematode compounds. The discovery of microbial secondary metabolites with broad-spectrum nematostatic or nematicidal properties can be hastened by drug screening approaches that include several nematode species and phenotypes. We cultured a collection of 22 soil-derived bacterial isolates that carry in their genomes putative pathways for production of unknown secondary metabolites. Isolates were cultured in various media to enhance natural product diversity and yield, and we evaluated culture filtrates for activity against two evolutionarily distinct nematode species: Clade V free-living nematode Caenorhabditis elegans and Clade III mammalian parasitic nematodes in the genus Brugia . Partitioned extracts from Pseudomonas sp. strain TE4607 stunted C. elegans development and caused motility defects in both blood-circulating larval and adult stages of Brugia . The primary active compound was identified as labradorin 1, an indole with known antibacterial and anticancer properties that had not been previously described as affecting nematodes. Notably, filtrates of Pseudomonas sp. TE4607 cultures attracted free-living nematodes in sensory assays, adding to evidence that certain Pseudomonas species modulate the behavior of free-living nematodes. These findings underscore the need to further explore the link between nematode sensory responses and whole-organism effects of microbial metabolites, with potential applications in anthelmintic discovery. Abstract Figure:
Open AccessNematicidal indole oxazoles and chemoattractants from soil bacteria
Ecological interactions between bacteria and nematodes in many environments provide a basis for the prediction that diverse bacteria produce anti-nematode compounds. The discovery of microbial secondary metabolites with broad-spectrum nematostatic or nematicidal properties can be hastened by drug screening approaches that include several nematode species and phenotypes. We cultured a collection of 22 soil-derived bacterial isolates that carry in their genomes putative pathways for production of unknown secondary metabolites. Isolates were cultured in various media to enhance natural product diversity and yield, and we evaluated culture filtrates for activity against two evolutionarily distinct nematode species: Clade V free-living nematode Caenorhabditis elegans and Clade III mammalian parasitic nematodes in the genus Brugia . Partitioned extracts from Pseudomonas sp. strain TE4607 stunted C. elegans development and caused motility defects in both blood-circulating larval and adult stages of Brugia . The primary active compound was identified as labradorin 1, an indole with known antibacterial and anticancer properties that had not been previously described as affecting nematodes. Notably, filtrates of Pseudomonas sp. TE4607 cultures attracted free-living nematodes in sensory assays, adding to evidence that certain Pseudomonas species modulate the behavior of free-living nematodes. These findings underscore the need to further explore the link between nematode sensory responses and whole-organism effects of microbial metabolites, with potential applications in anthelmintic discovery. Abstract Figure:
- Open Access
- 31 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Nemacol is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potential
Nematode parasites of humans and livestock pose a significant burden to human health, economic development, and food security. Anthelmintic drug resistance is widespread among parasites of livestock and many nematode parasites of humans lack effective treatments. Here, we present a nitrophenyl-piperazine scaffold that induces motor defects rapidly in the model nematode Caenorhabditis elegans. We call this scaffold Nemacol and show that it inhibits the vesicular acetylcholine transporter (VAChT), a target recognized by commercial animal and crop health groups as a viable anthelmintic target. We demonstrate that it is possible to create Nemacol analogs that maintain potent in vivo activity whilst lowering their affinity to the mammalian VAChT 10-fold. We also show that Nemacol enhances the ability of the anthelmintic Ivermectin to paralyze C. elegans and the ruminant nematode parasite Haemonchus contortus. Hence, Nemacol represents a promising new anthelmintic scaffold that acts through a validated anthelmintic target.
- 31 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessNemacol is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter with anthelmintic potential
Nematode parasites of humans and livestock pose a significant burden to human health, economic development, and food security. Anthelmintic drug resistance is widespread among parasites of livestock and many nematode parasites of humans lack effective treatments. Here, we present a nitrophenyl-piperazine scaffold that induces motor defects rapidly in the model nematode Caenorhabditis elegans. We call this scaffold Nemacol and show that it inhibits the vesicular acetylcholine transporter (VAChT), a target recognized by commercial animal and crop health groups as a viable anthelmintic target. We demonstrate that it is possible to create Nemacol analogs that maintain potent in vivo activity whilst lowering their affinity to the mammalian VAChT 10-fold. We also show that Nemacol enhances the ability of the anthelmintic Ivermectin to paralyze C. elegans and the ruminant nematode parasite Haemonchus contortus. Hence, Nemacol represents a promising new anthelmintic scaffold that acts through a validated anthelmintic target.
- Open Access
- 13 January 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-15
Multivariate chemogenomic screening prioritizes new macrofilaricidal leads
Development of direct acting macrofilaricides for the treatment of human filariases is hampered by limitations in screening throughput imposed by the parasite life cycle. In vitro adult screens typically assess single phenotypes without prior enrichment for chemicals with antifilarial potential. We developed a multivariate screen that identified dozens of compounds with submicromolar macrofilaricidal activity, achieving a hit rate of >50% by leveraging abundantly accessible microfilariae. Adult assays were multiplexed to thoroughly characterize compound activity across relevant parasite fitness traits, including neuromuscular control, fecundity, metabolism, and viability. Seventeen compounds from a diverse chemogenomic library elicited strong effects on at least one adult trait, with differential potency against microfilariae and adults. Our screen identified five compounds with high potency against adults but low potency or slow-acting microfilaricidal effects, at least one of which acts through a novel mechanism. We show that the use of microfilariae in a primary screen outperforms model nematode developmental assays and virtual screening of protein structures inferred with deep learning. These data provide new leads for drug development, and the high-content and multiplex assays set a new foundation for antifilarial discovery.
- 13 January 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-15
Open AccessMultivariate chemogenomic screening prioritizes new macrofilaricidal leads
Development of direct acting macrofilaricides for the treatment of human filariases is hampered by limitations in screening throughput imposed by the parasite life cycle. In vitro adult screens typically assess single phenotypes without prior enrichment for chemicals with antifilarial potential. We developed a multivariate screen that identified dozens of compounds with submicromolar macrofilaricidal activity, achieving a hit rate of >50% by leveraging abundantly accessible microfilariae. Adult assays were multiplexed to thoroughly characterize compound activity across relevant parasite fitness traits, including neuromuscular control, fecundity, metabolism, and viability. Seventeen compounds from a diverse chemogenomic library elicited strong effects on at least one adult trait, with differential potency against microfilariae and adults. Our screen identified five compounds with high potency against adults but low potency or slow-acting microfilaricidal effects, at least one of which acts through a novel mechanism. We show that the use of microfilariae in a primary screen outperforms model nematode developmental assays and virtual screening of protein structures inferred with deep learning. These data provide new leads for drug development, and the high-content and multiplex assays set a new foundation for antifilarial discovery.
- Open Access
- 12 October 2022
- Published by Springer Nature in Research Square
Bivariate, high-content screening of Brugia malayi microfilariae
The following protocol is for performing bivariate (motility and viability) phenotypic drug screens against Brugia spp. microfilariae (mf). It has been heavily optimized for utilization with an ImageXpress high-content imager, but only small adaptations will be necessary for usage with similar imaging platforms.Mf are used immediately after receipt/extraction, and the experiment should not be run longer than 48 hours, after which mf health rapidly deteriorates. We have had success recording motility at 12 hours post-treatment (hpt) and again at 36 hpt, after which mf are immediately stained for viability, as well as 24/48 hpt time points.The two phenotypes could be assayed separately, but we have found that not every compound that causes reduction in mf motility causes a concomitant loss of viability. Thus, the discriminatory power of the pipeline is increased by running both assays in parallel, using the same plates. We have run the experiment using 16 plates at a time which will necessitate several hours of imaging at the desired time points. If several plates are planned, drug addition will need to be staggered every 5-6 minutes in accordance with the time taken to completely image each plate.Image data can be analyzed via a variety of software, but we have designed wrmXpress for this purpose (1).
- 12 October 2022
- Published by Springer Nature in Research Square
Open AccessBivariate, high-content screening of Brugia malayi microfilariae
The following protocol is for performing bivariate (motility and viability) phenotypic drug screens against Brugia spp. microfilariae (mf). It has been heavily optimized for utilization with an ImageXpress high-content imager, but only small adaptations will be necessary for usage with similar imaging platforms.Mf are used immediately after receipt/extraction, and the experiment should not be run longer than 48 hours, after which mf health rapidly deteriorates. We have had success recording motility at 12 hours post-treatment (hpt) and again at 36 hpt, after which mf are immediately stained for viability, as well as 24/48 hpt time points.The two phenotypes could be assayed separately, but we have found that not every compound that causes reduction in mf motility causes a concomitant loss of viability. Thus, the discriminatory power of the pipeline is increased by running both assays in parallel, using the same plates. We have run the experiment using 16 plates at a time which will necessitate several hours of imaging at the desired time points. If several plates are planned, drug addition will need to be staggered every 5-6 minutes in accordance with the time taken to completely image each plate.Image data can be analyzed via a variety of software, but we have designed wrmXpress for this purpose (1).
- Open Access
- 12 October 2022
- Published by Springer Nature in Research Square
Multivariate screening of Brugia spp. adults
The following protocol is for performing multivariate (motility, fecundity, metabolism, and viability) phenotypic drug screens against Brugia spp. adults.Adults are allowed to recover in complete media after extraction and (if applicable) shipment in order to equilibrate. The assay is initiated the next day and terminated after 48 hrs, after which females will no longer release progeny.
- 12 October 2022
- Published by Springer Nature in Research Square
Open AccessMultivariate screening of Brugia spp. adults
The following protocol is for performing multivariate (motility, fecundity, metabolism, and viability) phenotypic drug screens against Brugia spp. adults.Adults are allowed to recover in complete media after extraction and (if applicable) shipment in order to equilibrate. The assay is initiated the next day and terminated after 48 hrs, after which females will no longer release progeny.
- Open Access
- 26 August 2022
- Published by Springer Nature in Research Square
Bivariate, high-content screening of Brugia malayi microfilariae
The following protocol is for performing bivariate (motility and viability) phenotypic drug screens against Brugia spp. microfilariae (mf). It has been heavily optimized for utilization with an ImageXpress high-content imager, but only small adaptations will be necessary for usage with similar imaging platforms.Mf are used immediately after receipt/extraction, and the experiment should not be run longer than 48 hours, after which mf health rapidly deteriorates. We have had success recording motility at 12 hours post-treatment (hpt) and again at 36 hpt, after which mf are immediately stained for viability, as well as 24/48 hpt time points.The two phenotypes could be assayed separately, but we have found that not every compound that causes reduction in mf motility causes a concomitant loss of viability. Thus, the discriminatory power of the pipeline is increased by running both assays in parallel, using the same plates. We have run the experiment using 16 plates at a time which will necessitate several hours of imaging at the desired time points. If several plates are planned, drug addition will need to be staggered every 5-6 minutes in accordance with the time taken to completely image each plate.Image data can be analyzed via a variety of software, but we have designed wrmXpress for this purpose (1).
- 26 August 2022
- Published by Springer Nature in Research Square
Open AccessBivariate, high-content screening of Brugia malayi microfilariae
The following protocol is for performing bivariate (motility and viability) phenotypic drug screens against Brugia spp. microfilariae (mf). It has been heavily optimized for utilization with an ImageXpress high-content imager, but only small adaptations will be necessary for usage with similar imaging platforms.Mf are used immediately after receipt/extraction, and the experiment should not be run longer than 48 hours, after which mf health rapidly deteriorates. We have had success recording motility at 12 hours post-treatment (hpt) and again at 36 hpt, after which mf are immediately stained for viability, as well as 24/48 hpt time points.The two phenotypes could be assayed separately, but we have found that not every compound that causes reduction in mf motility causes a concomitant loss of viability. Thus, the discriminatory power of the pipeline is increased by running both assays in parallel, using the same plates. We have run the experiment using 16 plates at a time which will necessitate several hours of imaging at the desired time points. If several plates are planned, drug addition will need to be staggered every 5-6 minutes in accordance with the time taken to completely image each plate.Image data can be analyzed via a variety of software, but we have designed wrmXpress for this purpose (1).